Untreated aHUS in adults carries risk of severe kidney damage
Adults with atypical hemolytic uremic syndrome (aHUS) in the U.K. who didn’t receive treatment with Soliris (eculizumab) had a 43% chance of developing end-stage kidney disease within five years, according to a study that found this severe form of kidney damage was less likely in children within the…